Author of

• 32148

  +

  EP1.14 - Targeted Therapy (ID 204)

  • Event: WCLC 2019
  • Type: E-Poster Viewing in the Exhibit Hall
  • Track: Targeted Therapy
  • Presentations: 1
  • Moderators:
  • Coordinates: 9/08/2019, 08:00 - 18:00, Exhibit Hall

  • 32165

    +

    EP1.14-13 - EGFR Mutation in Lung Adenocarcinoma: Real World Study from a Single Institute (ID 2537)

    08:00 - 18:00  |  Author(s): JINGHAN Li
    • Abstract

    Background
    

    To investigate the EGFR mutation in lung adenocarcinoma of real world.

    Method
    

    Patients diagnosed lung adenocarcinoma and performed EGFR mutation analysis in Liaoning Cancer Hospital & Institute from June 2014 to April 2018 were collected retrospectively. Gender, age, EGFR mutation status of patients were analyzed.

    Result
    

    There were 779 patients included in the study. Of all patients, 365 were male, 414 were female, median age was 60 years-old (range 29-80). EGFR mutation analysis showed that there were 417 mutation cases, 362 were negative, the overall mutation rate was 53.5%. For male patients, the mutation rate was 37.0% (135/365), and 68.1% for female patients (282/414). Seven hundred and sixty-one patients had one EGFR mutation type, 17 had two types, and 1 had three types. The most common type of EGFR mutation was Exon 21 L858R (204/436, 46.8%), and the second common was Exon 19 deletion (175/436, 40.4%), other mutation types were significantly less, including Exon 20 insertion (20/436, 4.6%), Exon 18 G719X (19/436, 4.4%), Exon 20 S768I (10/436, 2.3%), Exon 21 L861Q (5/436, 1.1%). Primary resistance of T790M mutation were found in 3 patients (0.7%), however, all the 3 cases had two types of mutations besides T790M mutation (2 Exon 19 deletion and 1 Exon 21 L858R).

    Conclusion
    

    The overall EGFR mutation rate was over 50% in our institution, and higher in female patients, about 70%. The most common mutations were Exon 21 L858R and Exon 19 deletion, and other mutation types were rare. Finally, T790M mutation often combined with the other type of EGFR mutations.

• 31515

  +

  P2.14 - Targeted Therapy (ID 183)

  • Event: WCLC 2019
  • Type: Poster Viewing in the Exhibit Hall
  • Track: Targeted Therapy
  • Presentations: 1
  • Moderators:
  • Coordinates: 9/09/2019, 10:15 - 18:15, Exhibit Hall

  • 31523

    +

    P2.14-06 - The Study of Rac3 Molecular Mechanism Through ERK Signaling Pathway in Lung Adenocarcinoma (ID 1252)

    10:15 - 18:15  |  Author(s): JINGHAN Li
    • Abstract

    Background
    

    To find out the relationship between Rac3 gene and prognosis of lung adenocarcinoma, the role of Rac3 in the proliferation and migration of lung adenocarcinoma cells, and the mechanism of Rac3 promoting the proliferation and migration of lung adenocarcinoma cells.

    Method
    

    542 patients with lung adenocarcinoma in the TCGA database were selected for analysis, the expression of Rac3 in cancer tissues and normal lung tissues were compared. Kaplan-Meier Plotter database was selected to analyze the relationship between Rac3 expression and 5-year overall survival rate of patients by Kaplan-Meier method. Human lung adenocarcinoma cell lines A549 and H1299 were used to build Rac3 knockdown and high-expression cell lines. The role of Rac3 in the proliferation and migration of lung adenocarcinoma cells was detected by cell proliferation and healing-wound test. The Rac3 knockdown cell lines were used to detect the changes of intracellular signaling pathways by serum starvation test and Western Blot experiment, screening out the signaling pathways with significant differences and study the biological function of them.

    Result
    

    The results of TCGA database analysis showed that Rac3 expression in 542 patients with lung adenocarcinoma was significantly higher than that in normal lung tissues, and the result is statistically significant (P<0.01). Kaplan-Meier survival analysis showed that patients with high Rac3 expression had a significantly shorter 5-year overall survival than those with low Rac3 expression (P<0.0001). In A549 and H1299 cell lines, Rac3 shRNA is used to build Rac3 knockdown and high expression cell lines by lentivirus infection. The proliferation and migration of lung adenocarcinoma cells were detected by cell proliferation test and healing-wound test. Compared with the control group, the proliferation and migration ability of Rac3-shRNA group was significantly decreased, while that of Rac3 high expression group was significantly increased (P < 0.01). Serum starvation test and Western Blot results showed that in A549 cell lines, the phosphorylation of ERK pathway was significantly reduced after Rac3 expression was knocked down by shRNA compared with the control group.

    Conclusion
    

    Rac3 is highly expressed in lung adenocarcinoma. The overall survival (OS) of patients with high Rac3 expression was significantly shorter than those with low Rac3 expression. Rac3 promotes the proliferation of lung adenocarcinoma cells. Rac3 promotes the migration of lung adenocarcinoma cells. Rac3 probably regulates the ERK signaling pathway to promote the proliferation in lung adenocarcinoma cells.